ArticleFrontiers in immunology2026
Predictive value of peripheral blood eosinophil levels and dynamics for efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer: a real-world study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterogeneous benefits from immunotherapy in advanced driver gene-negative non-small cell lung cancer (NSCLC) underscore the need for biomarkers predicting efficacy and immune-related adverse event (irAE) risk. Eosinophils, routinely measured in peripheral blood and involved in antitumor immunity, may serve as practical biomarkers for predicting the efficacy and safety of immune checkpoint inhibitors (ICIs). This retrospective study enrolled 316 consecutive patients with unresectable stage III-IV NSCLC treated with ICI-based regimens at Harbin Medical University Cancer Hospital (2016-2024). Peripheral absolute eosinophil count (AEC) and eosinophil percent (E%) were measured at baseline and after cycles 2 and 4. Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints. Associations with irAEs were also evaluated. Multivariable Cox analysis showed that increases in AEC and E% from baseline to cycle 4 (ΔAEC and ΔE%) were independently associated with OS (ΔAEC: aHR=0.88 per doubling, p=0.036; ΔE%: aHR=0.84 per doubling, p=0.006). Optimal cut-offs for cycle 4 AEC (0.22×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.